Stock of the Day

Zimmer Biomet (ZBH)

$100.19

-$0.72 (-0.7%)

Market Cap: $19.25B

About Zimmer Biomet

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E

.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Zimmer Biomet Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

• The company reported earnings per share (EPS) of $2.07 for the latest quarter, exceeding analyst expectations, which indicates strong financial performance and effective management.
• Zimmer Biomet Holdings, Inc. has shown a year-over-year revenue growth of approximately 4.8%, suggesting a positive trend in sales and market demand for its products.
• The current stock price is around $104, reflecting a stable valuation in the medical device sector, which can be attractive for long-term investors.
• The company has a solid return on equity of 13.12%, indicating efficient use of shareholders' equity to generate profits, which is a positive sign for potential investors.
• Zimmer Biomet Holdings, Inc. has a consistent dividend payout ratio of 23.36%, providing a reliable income stream for investors through dividends, which can be appealing in a low-interest-rate environment.

Zimmer Biomet Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

• The company has a net margin of 9.48%, which, while positive, may indicate that there is limited room for profit expansion compared to competitors in the industry.
• Analysts have mixed ratings on the stock, with a consensus rating of "Hold," suggesting that there may be uncertainty about its future performance.
• Recent insider selling activity, where an insider sold a significant number of shares, could raise concerns about the company's future prospects and insider confidence.
• Zimmer Biomet Holdings, Inc. operates in a highly competitive market, which may pose risks to maintaining its market share and profitability.
• The company’s guidance for FY 2026 EPS is set between 8.470-8.590, which may not meet the growth expectations of some investors looking for higher returns.

Recent News

• Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026 (prnewswire.com)